FDA gives Fast Track Designation to tebentafusp
The drug has already been granted orphan drug designation for melanoma by the FDA.
Read More
Tag: Immunocore
GSK picks third target in Immunocore discovery deal
GlaxoSmithKline has selected a third target in its collaboration with Oxford, UK-based Immunocore to discover multiple novel targets in cancer not addressable with antibody-based technologies.
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
